MedTrace Logo

Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir

NCT03980691 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2021-07-20

No results posted yet for this study

Summary

To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.

Conditions

Interventions

BIOLOGICAL

Chidamide with CAR-T or TCR-T cell therapy

HIV-1 specific therapy

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Guangzhou 8th People's Hospital

    lead OTHER

Principal Investigators

  • Weiping Cai, Bachelor · Guangzhou 8th People's Hospital China, Guangdong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980691 on ClinicalTrials.gov